News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chemokine Therapeutics Corp. (CTI.TO) Announces Three Posters Presented on Its Lead Compound, CTCE-9908, at the 2008 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Conference


10/28/2008 9:59:27 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 28, 2008) - Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease today announced that three posters were presented at the 20th European Organization for Research and Treatment of Cancer (EORTC) - National Cancer Institute (NCI) - American Association for Cancer Research (AACR) Symposium on Molecular Targets and Cancer Therapeutics held in Geneva, Switzerland, October 21-24, 2008.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES